Applied DNA Sciences, Inc. (APDN)
USD 1.15
(4.55%)
USD 1.15
(4.55%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.91 Million USD | 61.13% |
| 2022 | -15.21 Million USD | -132.12% |
| 2021 | -6.55 Million USD | -20.48% |
| 2020 | -5.44 Million USD | -651.68% |
| 2019 | 986.23 Thousand USD | 1452.25% |
| 2018 | -72.93 Thousand USD | 97.54% |
| 2017 | -2.95 Million USD | 33.92% |
| 2016 | -4.47 Million USD | 38.74% |
| 2015 | -7.31 Million USD | -1897.19% |
| 2014 | 406.86 Thousand USD | 106.4% |
| 2013 | -6.36 Million USD | -777.55% |
| 2012 | -724.78 Thousand USD | -173.69% |
| 2011 | 983.58 Thousand USD | -44.0% |
| 2010 | 1.75 Million USD | -20.06% |
| 2009 | 2.19 Million USD | -24.93% |
| 2008 | 2.92 Million USD | 309.23% |
| 2007 | 715.22 Thousand USD | -90.44% |
| 2006 | 7.47 Million USD | 1871.76% |
| 2005 | 379.23 Thousand USD | -86.39% |
| 2004 | 2.78 Million USD | 2754.7% |
| 2003 | -104.97 Thousand USD | -77656.3% |
| 2002 | -135.00 USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -2.15 Million USD | 3.85% |
| 2024 Q1 | -2.24 Million USD | 62.09% |
| 2024 Q3 | -9.57 Million USD | -344.16% |
| 2023 Q3 | -9.4 Million USD | 13.09% |
| 2023 Q4 | -5.91 Million USD | 37.09% |
| 2023 FY | -5.91 Million USD | 61.13% |
| 2023 Q1 | -12.87 Million USD | 15.37% |
| 2023 Q2 | -10.81 Million USD | 16.0% |
| 2022 Q2 | -6.51 Million USD | -136.97% |
| 2022 Q1 | -2.74 Million USD | 58.07% |
| 2022 FY | -15.21 Million USD | -132.12% |
| 2022 Q4 | -15.21 Million USD | -224.98% |
| 2022 Q3 | -4.68 Million USD | 28.11% |
| 2021 Q4 | -6.55 Million USD | 46.15% |
| 2021 Q2 | -13.92 Million USD | -310.24% |
| 2021 Q3 | -12.17 Million USD | 12.58% |
| 2021 Q1 | -3.39 Million USD | 37.61% |
| 2021 FY | -6.55 Million USD | -20.48% |
| 2020 Q2 | -7.17 Million USD | 0.09% |
| 2020 Q3 | -8.58 Million USD | -19.63% |
| 2020 Q1 | -7.18 Million USD | -828.35% |
| 2020 Q4 | -5.44 Million USD | 36.63% |
| 2020 FY | -5.44 Million USD | -651.68% |
| 2019 Q1 | -996.72 Thousand USD | -1266.63% |
| 2019 Q2 | 653.42 Thousand USD | 165.56% |
| 2019 FY | 986.23 Thousand USD | 1452.25% |
| 2019 Q3 | 1.7 Million USD | 161.47% |
| 2019 Q4 | 986.28 Thousand USD | -42.27% |
| 2018 Q2 | -3.7 Million USD | 22.15% |
| 2018 FY | -72.93 Thousand USD | 97.54% |
| 2018 Q4 | -72.93 Thousand USD | 97.1% |
| 2018 Q3 | -2.51 Million USD | 32.2% |
| 2018 Q1 | -4.76 Million USD | -60.98% |
| 2017 FY | -2.95 Million USD | 33.92% |
| 2017 Q4 | -2.95 Million USD | -23.18% |
| 2017 Q3 | -2.4 Million USD | 40.23% |
| 2017 Q2 | -4.02 Million USD | 40.01% |
| 2017 Q1 | -6.7 Million USD | -49.61% |
| 2016 Q3 | -7.08 Million USD | 27.58% |
| 2016 FY | -4.47 Million USD | 38.74% |
| 2016 Q4 | -4.47 Million USD | 36.79% |
| 2016 Q1 | -12.38 Million USD | -69.35% |
| 2016 Q2 | -9.78 Million USD | 20.97% |
| 2015 Q1 | -2.87 Million USD | -805.77% |
| 2015 FY | -7.31 Million USD | -1897.19% |
| 2015 Q4 | -7.31 Million USD | 31.85% |
| 2015 Q3 | -10.73 Million USD | -990.41% |
| 2015 Q2 | -984.05 Thousand USD | 65.73% |
| 2014 Q2 | -1.98 Million USD | 52.65% |
| 2014 Q3 | -2.02 Million USD | -1.89% |
| 2014 FY | 406.86 Thousand USD | 106.4% |
| 2014 Q4 | 406.86 Thousand USD | 120.09% |
| 2014 Q1 | -4.19 Million USD | 33.98% |
| 2013 Q2 | -4.4 Million USD | -347.54% |
| 2013 FY | -6.36 Million USD | -777.55% |
| 2013 Q3 | -1.83 Million USD | 58.42% |
| 2013 Q4 | -6.36 Million USD | -247.22% |
| 2013 Q1 | -984.41 Thousand USD | -35.82% |
| 2012 Q3 | -1 Million USD | -65.87% |
| 2012 Q1 | 1.15 Million USD | 17.18% |
| 2012 FY | -724.78 Thousand USD | -173.69% |
| 2012 Q4 | -724.78 Thousand USD | 27.96% |
| 2012 Q2 | -606.57 Thousand USD | -152.63% |
| 2011 FY | 983.58 Thousand USD | -44.0% |
| 2011 Q4 | 983.58 Thousand USD | -66.54% |
| 2011 Q3 | 2.93 Million USD | 27.73% |
| 2011 Q2 | 2.3 Million USD | 6.56% |
| 2011 Q1 | 2.15 Million USD | 22.94% |
| 2010 FY | 1.75 Million USD | -20.06% |
| 2010 Q2 | 2.34 Million USD | -16.21% |
| 2010 Q3 | 2.27 Million USD | -2.92% |
| 2010 Q1 | 2.8 Million USD | 27.56% |
| 2010 Q4 | 1.75 Million USD | -22.96% |
| 2009 FY | 2.19 Million USD | -24.93% |
| 2009 Q1 | 1.01 Million USD | -65.26% |
| 2009 Q2 | 912.45 Thousand USD | -10.26% |
| 2009 Q3 | 1.51 Million USD | 65.7% |
| 2009 Q4 | 2.19 Million USD | 45.32% |
| 2008 Q2 | 2.58 Million USD | 85.7% |
| 2008 Q1 | 1.39 Million USD | 94.54% |
| 2008 Q3 | 2.58 Million USD | 0.0% |
| 2008 Q4 | 2.92 Million USD | 13.28% |
| 2008 FY | 2.92 Million USD | 309.23% |
| 2007 FY | 715.22 Thousand USD | -90.44% |
| 2007 Q3 | 1.71 Million USD | -87.48% |
| 2007 Q4 | 715.22 Thousand USD | -58.2% |
| 2007 Q1 | 5.99 Million USD | -19.81% |
| 2007 Q2 | 13.66 Million USD | 127.83% |
| 2006 Q3 | 1.78 Million USD | 60.94% |
| 2006 Q4 | 7.47 Million USD | 318.77% |
| 2006 Q1 | 795.9 Thousand USD | 109.87% |
| 2006 Q2 | 1.1 Million USD | 39.4% |
| 2006 FY | 7.47 Million USD | 1871.76% |
| 2005 Q4 | 379.23 Thousand USD | 149.41% |
| 2005 Q3 | -767.46 Thousand USD | 69.9% |
| 2005 Q2 | -2.55 Million USD | -193.16% |
| 2005 Q1 | 2.73 Million USD | -1.77% |
| 2005 FY | 379.23 Thousand USD | -86.39% |
| 2004 Q1 | -402.54 Thousand USD | -283.49% |
| 2004 Q3 | 1.3 Million USD | 137.19% |
| 2004 Q4 | 2.78 Million USD | 113.06% |
| 2004 FY | 2.78 Million USD | 2754.7% |
| 2004 Q2 | 551.43 Thousand USD | 236.99% |
| 2003 Q3 | 9858.00 USD | 138.13% |
| 2003 Q1 | -83.00 USD | 38.52% |
| 2003 Q2 | -25.85 Thousand USD | -31048.19% |
| 2003 Q4 | -104.97 Thousand USD | -1164.83% |
| 2003 FY | -104.97 Thousand USD | -77656.3% |
| 2002 Q2 | -135.00 USD | 0.0% |
| 2002 Q4 | -135.00 USD | 0.0% |
| 2002 FY | -135.00 USD | 0.0% |
| 2002 Q1 | -135.00 USD | 0.0% |
| 2002 Q3 | -135.00 USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | -135.00 USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 85.01% |
| Aspira Women's Health Inc. | -331 Thousand USD | -1686.719% |
| Biodesix, Inc. | 34.3 Million USD | 117.239% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -2.038% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -375.814% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -375.814% |
| Bionano Genomics, Inc. | 34.88 Million USD | 116.954% |
| CareDx, Inc | -47.97 Million USD | 87.673% |
| Check-Cap Ltd. | -24.75 Million USD | 76.111% |
| Castle Biosciences, Inc. | -83.53 Million USD | 92.92% |
| DarioHealth Corp. | -7.54 Million USD | 21.648% |
| Exact Sciences Corporation | 1.94 Billion USD | 100.303% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 92.837% |
| Guardant Health, Inc. | 220.22 Million USD | 102.685% |
| ICON Public Limited Company | 3.56 Billion USD | 100.166% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 101.197% |
| Illumina, Inc. | 1.21 Billion USD | 100.487% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -8.861% |
| iSpecimen Inc. | -2.14 Million USD | -175.402% |
| Standard BioTools Inc. | 46.5 Million USD | 112.717% |
| MDxHealth SA | 18.88 Million USD | 131.316% |
| 23andMe Holding Co. | -141.37 Million USD | 95.817% |
| Medpace Holdings, Inc. | -103.32 Million USD | 94.276% |
| Myriad Genetics, Inc. | 88.1 Million USD | 106.713% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 1790.426% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -142.428% |
| NeoGenomics, Inc. | 269.19 Million USD | 102.197% |
| Neogen Corporation | 735.62 Million USD | 100.804% |
| Inotiv, Inc. | 382.14 Million USD | 101.548% |
| Natera, Inc. | -200.1 Million USD | 97.044% |
| OpGen, Inc. | 11.89 Million USD | 149.732% |
| OPKO Health, Inc. | 230.68 Million USD | 102.564% |
| Psychemedics Corporation | 334 Thousand USD | 1870.671% |
| Prenetics Global Limited | -43.33 Million USD | 86.353% |
| Prenetics Global Limited | -43.33 Million USD | 86.353% |
| Precipio, Inc. | -386 Thousand USD | -1432.135% |
| Personalis, Inc. | -8.02 Million USD | 26.277% |
| RadNet, Inc. | 1.14 Billion USD | 100.515% |
| Sera Prognostics, Inc. | -2.02 Million USD | -192.485% |
| Sotera Health Company | 2.02 Billion USD | 100.292% |
| Neuronetics, Inc. | 2.79 Million USD | 311.442% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 61.439% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 61.439% |
| Trinity Biotech plc | 63.73 Million USD | 109.279% |
| T2 Biosystems, Inc. | 33.8 Million USD | 117.493% |
| Twist Bioscience Corporation | -192.4 Million USD | 96.926% |
| Exagen Inc. | -12.77 Million USD | 53.695% |